Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTRAY extension study of sotatercept in pulmonary arterial hypertension
NL-OMON59913Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Number of participants with one or more adverse events and Number of participants who discontinue study intervention due to an adverse event. Started Jun 2025; status: active, not recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON59913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59913.